Un estudio realizado por científicos de la Universidad de Ginebra (UNIGE) y la Clinique romande de réadaptation (CRR) en Sión ha identificado las marcas epigenéticas que aparecen en pacientes c...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today report...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...
Read moreNuevo indicador para promover la igualdad de género Se ha conformado con 30 sociedades cotizadas españolas, entre las que se encuentran ORYZON, Banco Santander, BBVA, Bankinter, Iberdrola y Almir
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presents ...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announce...
Read moreOryzon Genomics, S.A., a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, has announced that Dr. Ana Limón has b...
Read moreEl objetivo de este grupo de investigadores era descubrir las bases epigenéticas de la anorexia nerviosa, uno de los trastornos alimentarios con mayor mortalidad entre las patologías psiquiátricas....
Read moreEl tiempo de floración es un importante carácter agronómico que tiene un impacto directo en el rendimiento de los cultivos. Las plantas controlan cuándo florecer en respuesta a una serie de estím...
Read moreResearch and development (R&D) expenses were $3.9 and $14.8 million for the quarter and 12 months ended December 31, 2021, compared to $3.4 and $13.6 million for the quarter and 12 months ended Decemb...
Read moreOryzon Genomics has announced today that it has received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) for iadademstat is now approv...
Read moreDr. Faller has over 30 years of clinical hematology/oncology expertise and broad drug development experience in the design and execution of early to registrational clinical programs across oncology an...
Read more